Dissemination (Meeting Coverage)

Atezolizumab plus bevacizumab (A+B) is the new standard of care for first-line treatment of...

In the treatment of hepatocellular carcinoma (HCC), immune checkpoint inhibitor (ICI) based...

Hepatocellular carcinoma (HCC) is the most rapidly expanding cause of cancer-related mortality in...

Patients with chronic lymphocytic leukemia (CLL) infected with COVID-19 during the most recent...

Measurable/minimal residual disease (MRD) assessment by qPCR was strongly associated with clinical...

The triplet combination of azacitidine, venetoclax, and gilteritinib induced high response rates...

Patients with relapsed or refractory mantle cell lymphoma (MCL) and a high CAR-hematotox score had...

A new, real-world study using more than 2 years of EMRs shows that patients with chronic...

Metabolic tumor volume (MTV) was reported at the 2022 annual meeting of the American Society of...

measurable residual disease (MRD)-negative showed an overall survival (OS) benefit if they were...

Post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil outperformed...

Odronextamab, an investigational bi-specific antibody targeting CD20 and CD3, showed promising...

Consolidation high-dose chemotherapy followed by autologous stem cell transplantation (HCT/ASCT)...

Intensive chemotherapy, in advance of allogeneic hematopoietic cell transplantation (allo-HCT),...

The 5-year follow-up data of the CAPTIVATE study demonstrated that first-line ibrutinib plus...

In patients with previously untreated mantle cell lymphoma (MCL), autologous stem cell...

High-dose methotrexate was not associated with a reduction in the risk for CNS relapse compared...

Triplet therapy of azacitidine, venetoclax, and magrolimab was safe as first-line therapy in...

Almost one-third of residents with gout living in aged care facilities did not receive...

Early findings from the PROTECT trial,1 presented at the 2022 American Society of Nephrology’s...